A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer ...

Johnson & Johnson (NYSE:JNJ) reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01. The pharmaceutical giant reported sales of $22.52 billion, up 5 ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC. Entered into clinical tr ...

Growth was driven by Darzalex (daratumumab), Erleada (apalutamide), Carvykti (ciltacabtagene autoleucel), Tremfya (guselkumab), and Spravato (esketamine), driven by continued strong share gains ...

The man's PSA was recorded at 1.09 ng/mL. As the findings were "suggestive of disease progression", doctors began treating him with apalutamide, a type of hormone therapy used to treat prostate ...